SMT202400418T1 - Inibitori a piccola molecola di chinasi che induce nf-κb - Google Patents

Inibitori a piccola molecola di chinasi che induce nf-κb

Info

Publication number
SMT202400418T1
SMT202400418T1 SM20240418T SMT202400418T SMT202400418T1 SM T202400418 T1 SMT202400418 T1 SM T202400418T1 SM 20240418 T SM20240418 T SM 20240418T SM T202400418 T SMT202400418 T SM T202400418T SM T202400418 T1 SMT202400418 T1 SM T202400418T1
Authority
SM
San Marino
Prior art keywords
small molecule
molecule inhibitors
inducing kinase
kinase
inducing
Prior art date
Application number
SM20240418T
Other languages
English (en)
Italian (it)
Inventor
Wenying Chai
Kevin D Kreutter
J Kent Barbay
Wendy Eccles
Michael D Hack
Aaron T Herrmann
William M Jones
Paul J Krawczuk
Alec D Lebsack
Daniel J Pippel
Alexander R Rovira
Ronald L Wolin
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SMT202400418T1 publication Critical patent/SMT202400418T1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SM20240418T 2019-05-31 2020-05-29 Inibitori a piccola molecola di chinasi che induce nf-κb SMT202400418T1 (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962855144P 2019-05-31 2019-05-31
US201962907833P 2019-09-30 2019-09-30
PCT/EP2020/065024 WO2020239999A1 (en) 2019-05-31 2020-05-29 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE
EP20733688.4A EP3976597B1 (en) 2019-05-31 2020-05-29 Small molecule inhibitors of nf-kb inducing kinase

Publications (1)

Publication Number Publication Date
SMT202400418T1 true SMT202400418T1 (it) 2024-11-15

Family

ID=71108552

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20240418T SMT202400418T1 (it) 2019-05-31 2020-05-29 Inibitori a piccola molecola di chinasi che induce nf-κb

Country Status (37)

Country Link
US (2) US11254673B2 (enExample)
EP (2) EP4467199A3 (enExample)
JP (2) JP7547387B2 (enExample)
KR (1) KR20220027871A (enExample)
CN (2) CN118908957A (enExample)
AU (1) AU2020282005B2 (enExample)
BR (1) BR112021023796A2 (enExample)
CL (1) CL2021003142A1 (enExample)
CO (1) CO2021017838A2 (enExample)
CR (1) CR20210587A (enExample)
DK (1) DK3976597T3 (enExample)
DO (1) DOP2021000244A (enExample)
EC (1) ECSP21093623A (enExample)
ES (1) ES2989387T3 (enExample)
FI (1) FI3976597T3 (enExample)
HR (1) HRP20241352T1 (enExample)
HU (1) HUE068694T2 (enExample)
IL (1) IL288387B2 (enExample)
JO (1) JOP20210318B1 (enExample)
LT (1) LT3976597T (enExample)
MA (1) MA56038B1 (enExample)
MD (1) MD3976597T2 (enExample)
MX (1) MX2021014679A (enExample)
MY (1) MY205653A (enExample)
PE (1) PE20220768A1 (enExample)
PH (1) PH12021553011A1 (enExample)
PL (1) PL3976597T3 (enExample)
PT (1) PT3976597T (enExample)
RS (1) RS66105B1 (enExample)
SA (1) SA521430960B1 (enExample)
SG (1) SG11202112994WA (enExample)
SI (1) SI3976597T1 (enExample)
SM (1) SMT202400418T1 (enExample)
TW (2) TWI850390B (enExample)
UA (1) UA130430C2 (enExample)
UY (1) UY38721A (enExample)
WO (1) WO2020239999A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3141826A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CA3142351A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
UA130430C2 (uk) * 2019-05-31 2026-02-18 Янссен Фармацевтика Нв НИЗЬКОМОЛЕКУЛЯРНІ ІНГІБІТОРИ КІНАЗИ, ЩО ІНДУКУЄ NF-kB
CA3257152A1 (en) * 2022-05-11 2023-11-16 Janssen Pharmaceutica Nv Pyrrolidine derivatives useful as NF-κB induction kinase inhibitors
US20250304567A1 (en) * 2022-05-11 2025-10-02 Janssen Pharmaceutica Nv Pyrrolidione derivatives as inhibitors of nf kappa b inducing kinase
AU2023410324A1 (en) 2022-12-22 2025-05-15 Boehringer Ingelheim International Gmbh Crystalline forms of a her2 inhibitor
WO2025020886A1 (zh) * 2023-07-27 2025-01-30 浙江星浩澎博医药有限公司 氮杂喹唑啉环衍生物及其用途
CN121568696A (zh) 2023-07-28 2026-02-24 勃林格殷格翰国际有限公司 制备her2抑制剂的方法
WO2025235874A1 (en) * 2024-05-10 2025-11-13 Schrödinger, Inc. Heterocyclics as egfr inhibitors
WO2026029041A1 (ja) * 2024-07-30 2026-02-05 日本たばこ産業株式会社 ピラゾロピリミジン化合物及びその医薬用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
US7132428B2 (en) 2003-07-03 2006-11-07 Aventis Pharmaceuticals Inc. Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders
EP1773781A2 (en) * 2004-08-03 2007-04-18 Wyeth Indazoles useful in treating cardiovascular diseases
WO2006053277A2 (en) 2004-11-12 2006-05-18 Chippac, Inc. Wire bond interconnection
JP2011525915A (ja) 2008-06-26 2011-09-29 アムジエン・インコーポレーテツド キナーゼ阻害薬としてのアルキニルアルコール類
US20110183975A1 (en) 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
MX2013010513A (es) * 2011-03-16 2013-10-07 Hoffmann La Roche Compuestos de alcohol 6,5-heterociclil-propargilico y usos de los mismos.
US9034866B2 (en) 2012-02-17 2015-05-19 Genentech, Inc. Tricyclic compounds and methods of use therefor
US8859553B2 (en) 2012-07-30 2014-10-14 Astar Biotech Llc Protein kinase inhibitors
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
CN105658639A (zh) * 2013-08-22 2016-06-08 豪夫迈·罗氏有限公司 炔基醇和应用方法
JP2016533385A (ja) 2013-08-22 2016-10-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ アルキニルアルコール及び使用方法
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物
EP3209654B1 (en) 2014-10-23 2018-10-03 Janssen Pharmaceutica N.V. New pyrazole derivatives as nik inhibitors
CA2960336C (en) 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Compounds as nik inhibitors
EA033238B1 (ru) 2014-10-23 2019-09-30 Янссен Фармацевтика Нв Новые производные тиенопиримидина в качестве ингибиторов nik
KR102523405B1 (ko) 2014-10-23 2023-04-18 얀센 파마슈티카 엔.브이. Ｎｉｋ 억제제로서의 신규 피라졸로피리미딘 유도체
WO2016135163A1 (en) 2015-02-25 2016-09-01 F. Hoffmann-La Roche Ag Alkynyl alcohols and methods of use
JP6910359B2 (ja) 2016-01-22 2021-07-28 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｉｋ阻害剤としての新たな置換されたシアノインドリン誘導体
KR102720461B1 (ko) 2016-01-22 2024-10-21 잔센파마슈티카엔.브이. Nik 억제제로서의 신규 6원 헤테로방향족 치환된 시아노인돌린 유도체
ES2805976T3 (es) 2016-06-30 2021-02-16 Janssen Pharmaceutica Nv Derivados heteroaromáticos en calidad de inhibidores de NIK
WO2018002219A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors
JP7140751B2 (ja) 2016-08-24 2022-09-21 エフ．ホフマン－ラ ロシュ アーゲー ２－アザビシクロ［３．１．０］ヘキサン－３－オン誘導体及び使用方法
CN109863142B (zh) * 2016-08-24 2022-06-10 豪夫迈·罗氏有限公司 2-氮杂双环[3.1.0]己烷-3-酮衍生物及使用方法
KR102662373B1 (ko) 2017-07-06 2024-04-29 얀센 파마슈티카 엔브이 Nik 억제제로서의 신규 치환 아자인돌린 유도체
CN109810110B (zh) * 2017-11-22 2023-01-24 中国科学院上海药物研究所 一种具有2-氨基嘧啶结构的化合物，其制备方法和用途
CA3141826A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
SG11202112391UA (en) 2019-05-31 2021-12-30 Sage Therapeutics Inc Neuroactive steroids and compositions thereof
CA3142351A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
UA130430C2 (uk) * 2019-05-31 2026-02-18 Янссен Фармацевтика Нв НИЗЬКОМОЛЕКУЛЯРНІ ІНГІБІТОРИ КІНАЗИ, ЩО ІНДУКУЄ NF-kB
CA3139018A1 (en) 2019-05-31 2020-12-03 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as p2x3 inhibitors
PE20221038A1 (es) 2019-09-30 2022-06-17 Incyte Corp Compuestos de pirido[3,2-d] pirimidina como inmunomoduladores

Also Published As

Publication number Publication date
ECSP21093623A (es) 2022-01-31
TW202110842A (zh) 2021-03-16
ES2989387T3 (es) 2024-11-26
MA56038A (fr) 2022-04-06
DK3976597T3 (da) 2024-09-09
LT3976597T (lt) 2024-10-10
HUE068694T2 (hu) 2025-01-28
TWI850390B (zh) 2024-08-01
US11827634B2 (en) 2023-11-28
DOP2021000244A (es) 2022-04-18
CN118908957A (zh) 2024-11-08
IL288387B2 (en) 2026-01-01
TWI906955B (zh) 2025-12-01
HRP20241352T1 (hr) 2024-12-20
SA521430960B1 (ar) 2024-11-12
JP2022534302A (ja) 2022-07-28
JOP20210318B1 (ar) 2025-10-01
CR20210587A (es) 2022-02-11
US20210300918A1 (en) 2021-09-30
EP4467199A3 (en) 2025-03-05
IL288387A (en) 2022-01-01
IL288387B1 (en) 2025-09-01
CO2021017838A2 (es) 2022-01-17
MX2021014679A (es) 2022-04-06
UA130430C2 (uk) 2026-02-18
AU2020282005A1 (en) 2021-12-23
CN114222737A (zh) 2022-03-22
PT3976597T (pt) 2024-10-22
KR20220027871A (ko) 2022-03-08
CA3143350A1 (en) 2020-12-03
CL2021003142A1 (es) 2022-08-19
MA56038B1 (fr) 2024-11-29
JOP20210318A1 (ar) 2023-01-30
SI3976597T1 (sl) 2024-11-29
JP2024167319A (ja) 2024-12-03
US11254673B2 (en) 2022-02-22
BR112021023796A2 (pt) 2022-02-08
PH12021553011A1 (en) 2022-11-07
EP3976597A1 (en) 2022-04-06
WO2020239999A1 (en) 2020-12-03
EP4467199A2 (en) 2024-11-27
JP7547387B2 (ja) 2024-09-09
SG11202112994WA (en) 2021-12-30
MY205653A (en) 2024-11-02
PE20220768A1 (es) 2022-05-16
UY38721A (es) 2020-11-30
FI3976597T3 (fi) 2024-09-25
MD3976597T2 (ro) 2025-01-31
PL3976597T3 (pl) 2024-12-16
CN114222737B (zh) 2024-07-26
US20240199605A1 (en) 2024-06-20
EP3976597B1 (en) 2024-08-28
RS66105B1 (sr) 2024-11-29
AU2020282005B2 (en) 2026-02-12
US20230080834A1 (en) 2023-03-16
TW202517638A (zh) 2025-05-01

Similar Documents

Publication Publication Date Title
IL288387A (en) Small molecule inhibitors of nf-kb factor kinase
IL292643B1 (en) ras inhibitors
IL320513A (en) RAS inhibitors
ZA202203770B (en) Pharmaceutical combination of prmt5 inhibitors
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
LT4146348T (lt) Nek7 kinazės inhibitoriai
IL270693A (en) Glucuronide prodrugs of janus kinase inhibitors
LT3700902T (lt) Trpc6 inhibitoriai
HRP20260058T1 (hr) Dozni oblici za tyk2 inhibitore
EP3927700A4 (en) KINAS INHIBITORS
PL3496722T3 (pl) Kompozycje farmaceutyczne zawierające inhibitory kinazy białkowej Akt
IL313548A (en) MET kinase inhibitors
IL279314A (en) Small molecule inhibitors of the JAK family of kinases
EP3999064A4 (en) Inhibitors of tyrosine kinase
IL281599A (en) TYK2 kinase inhibitors
IL277869A (en) Substituted propanamides as nuclease inhibitors
SG10201909596RA (en) Synthesis of Tyrosine Kinase Inhibitors
ZA201908372B (en) Pyridoquinazoline derivatives useful as protein kinase inhibitors
GB201807845D0 (en) Kinase Inhibitors
HK40099704A (en) Small molecule inhibitors of nf-kb inducing kinase
GB201914388D0 (en) Kinase inhibitors
HK40075155A (en) Inhibitors of tyrosine kinase
HK40015193A (en) Glucuronide prodrugs of janus kinase inhibitors